Cargando…

PB2345: ADAPTING PATIENT EDUCATIONAL APPROACHES IN PYRUVATE KINASE DEFICIENCY: EUROPE AND NORTH AMERICA FINDINGS FROM THE AAC PATIENT AND CAREGIVER SURVEY

Detalles Bibliográficos
Autores principales:	Barcellini, W., Grace, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429859/ http://dx.doi.org/10.1097/01.HS9.0000852204.92713.7c

Ejemplares similares

PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023)

PB2359: HEALTHCARE RESOURCE UTILIZATION OF ADULT PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A REAL WORLD STUDY USING US VETERANS HEALTH ADMINISTRATION DATA
por: Zagadailov, E., et al.
Publicado: (2022)

PB2547: ESTIMATING HEALTH-RELATED QUALITY OF LIFE IN ADULT PYRUVATE KINASE DEFICIENCY: A TIME TRADE-OFF UTILITY STUDY
por: Higa, Sara, et al.
Publicado: (2023)

PB1990: GLYCOLYTIC ACTIVITY AND EFFECT OF EX-VIVO TREATMENT WITH THE PYRUVATE KINASE (PK) ACTIVATOR AG-946 IN RED BLOOD CELLS FROM LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS: A PROOF-OF-CONCEPT STUDY
por: Fattizzo, Bruno, et al.
Publicado: (2023)

PB2248: CONCOMITANT HEREDITARY SPHEROCYTOSIS AND PYRUVATE KINASE DEFICIENCY IN A SPANISH FAMILY WITH CHRONIC HEMOLYTIC ANEMIA. CONTRIBUTION OF LASER EKTACYTOMETRY TO CLINICAL DIAGNOSIS
por: Vives Corrons, J.-L., et al.
Publicado: (2022)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
por: Traets, Marissa, et al.
Publicado: (2023)

PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

PB1955: THE AGENDA FOR FUTURE MULTIPLE MYELOMA RESEARCH ACCORDING TO PATIENTS, CAREGIVERS, AND CLINICIANS
por: Fowler, S., et al.
Publicado: (2022)

Pyruvate Kinase Deficiency: Current Challenges and Future Prospects
por: Fattizzo, Bruno, et al.
Publicado: (2022)

The variable manifestations of disease in pyruvate kinase deficiency and their management
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Comorbidities and complications in adults with pyruvate kinase deficiency
por: Boscoe, Audra N., et al.
Publicado: (2021)

PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY
por: Crisà, Elena, et al.
Publicado: (2023)

PB1935: MANAGEMENT OF NON-SEVERE APLASTIC ANEMIA: LABORATORY WORKUP AND TREATMENT PATTERNS.
por: Cassanello, G., et al.
Publicado: (2022)

Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease‐specific assessments
por: Salek, Sam, et al.
Publicado: (2020)

P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: van Beers, Eduard, et al.
Publicado: (2023)

PB2567: THE EFFECT OF BLOOD DONATIONS ON IRON DEFICIENCY IN BLOOD DONORS
por: Lastochkina, Daria, et al.
Publicado: (2023)

PB1978: PATIENT-CENTREDNESS IS PIVOTAL IN A PROSPECTIVE DOSE REDUCTION TRIAL OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
por: Djodikromo, Melissa, et al.
Publicado: (2023)

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: van Beers, E. J., et al.
Publicado: (2022)

PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
por: Cooper, Nichola, et al.
Publicado: (2023)

PB2219: A REAL-WORLD EXPERIENCE WITH HEALTHCARE RESOURCE UTILIZATION PATTERNS AND RELATED COSTS IN PATIENTS WITH SICKLE CELL DISEASE IN NORTH LEBANON
por: Inati, A., et al.
Publicado: (2022)

PB2026: CONSENSUS STATEMENT: IMPORTANCE OF TIMELY ACCESS TO MULTIPLE MYELOMA DIAGNOSIS AND TREATMENT IN CENTRAL AMERICA AND THE CARIBBEAN
por: Pimentel, M., et al.
Publicado: (2022)

PB2652: EVALUATION OF 6 CASES WITH FXIII DEFICIENCY: SINGLE CENTRE EXPERIENCE
por: Sahin, Fahri, et al.
Publicado: (2023)

PB1834: ACQUIRED FACTOR VII DEFICIENCY ASSOCIATED WITH ACUTE MYELOID LEUKEMIA
por: Hafsa, Haifa, et al.
Publicado: (2023)

PB2552: VAYHIA: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IANALUMAB VS PLACEBO IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA THAT FAILED ≥1 LINE OF TREATMENT
por: Barcellini, Wilma, et al.
Publicado: (2023)

PB2326: SAFE AND EFFECTIVE PROPHYLAXIS WITH PLASMA-DERIVED FACTOR X CONCENTRATE IN AN ELDERLY PATIENT WITH HEREDITARY FACTOR X DEFICIENCY
por: Patel, H., et al.
Publicado: (2022)

PB2604: THE ROLE OF THE GUT MICROBIOTA IN MEDIATING BONE MARROW MESENCHYMAL STEM CELLS DEFICIENCY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN PREGNANCY
por: Chen, Qi, et al.
Publicado: (2023)

Evaluation of the main regulators of systemic iron homeostasis in pyruvate kinase deficiency
por: Zaninoni, Anna, et al.
Publicado: (2023)

PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
por: Zaja, Francesco, et al.
Publicado: (2023)

PB2546: DIAGNOSTIC POWER OF ERYTHROCYTE AND RETICULOCYTE AUTOMATIC PARAMETERS IN THE SCREENING FOR CONGENITAL HEMOLYTIC ANEMIAS
por: Bianchi, Paola, et al.
Publicado: (2023)

PB2660: HEREDITARY COAGULATION FACTOR FVII DEFICIENCY CAUSED BY COMPOUND HETEROZYGOUS MUTATIONS
por: Zhou, Rongfu, et al.
Publicado: (2023)

PB2526: UMBILICAL CORD BLOOD SCREENING FOR SICKLE CELL DISEASE: A PILOT STUDY IN THE NORTH OF TUNISIA
por: Ouragini, Houyem, et al.
Publicado: (2023)

PB2061: A NEW DIAGNOSTIC TOOL BASED ON MOLECULAR APPROACHES APPLICABLE TO ROUTINE CLINICAL USE FOR FANCONI ANEMIA PATIENTS ORIGINATING FROM NORTH AFRICA
por: Kraiem, Olfa, et al.
Publicado: (2023)

PB2679: MIXED-METHOD, CROSS-SECTIONAL SURVEY TO DESCRIBE FEELINGS, PERCEPTION, AND EXPERIENCE OF MULTIPLE MYELOMA PATIENTS WHO SWITCHED FROM INTRAVENOUS DARATUMUMAB TO THE SUBCUTANEOUS FORMULATION IN EUROPE
por: Magarotto, Valeria, et al.
Publicado: (2023)

PB2398: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA IN 2 CENTERS OF BOGOTÁ – COLOMBIA: THE LARGEST CASE SERIES IN LATIN AMERICA
por: Cynthia Fuentes-Lacouture, Maria, et al.
Publicado: (2023)

PB1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS
por: Bougherira, Soraya
Publicado: (2023)

Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial
por: Andrae, David A., et al.
Publicado: (2023)

PB2282: MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA
por: Smirnova, Svetlana, et al.
Publicado: (2023)

PB2563: IRON DEFICIENCY ANEMIA: A MONOCENTRIC EXPERIENCE OF THE HAEMATOLOGY DEPARTMENT OF MONASTIR, TUNISIA
por: Bouhoula, Donia, et al.
Publicado: (2023)

Comment on: Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis: reply
por: Esen, Idil, et al.
Publicado: (2022)

PB2317: COINHERITANCE OF COMBINED FACTOR VII AND FACTOR XIII DEFICIENCY IS ASSOCIATED WITH A MILD BLEEDING PHENOTYPE IN PATIENT WITH NON-TRANSFUSION DEPENDENT THALASSEMIA
por: Alshareef, O., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_225hh85joe47qqnqm7p1kt7p3j